Patents Assigned to Titan Pharmaceuticals, Inc.
-
Publication number: 20210007973Abstract: The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.Type: ApplicationFiled: October 5, 2017Publication date: January 14, 2021Applicant: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. PATEL, Sunil SREEDHARAN, Sunil R. BHONSLE
-
Patent number: 10123971Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: GrantFiled: March 13, 2013Date of Patent: November 13, 2018Assignee: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Sunil R. Bhonsle
-
Patent number: 10111830Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: GrantFiled: March 16, 2011Date of Patent: October 30, 2018Assignee: TITAN PHARMACEUTICALS, INC.Inventors: Rajesh A. Patel, Sunil R. Bhonsle
-
Patent number: 9278163Abstract: The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.Type: GrantFiled: October 3, 2014Date of Patent: March 8, 2016Assignee: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo, Lauren Costantini, Sofie Kleppner
-
Patent number: 8852623Abstract: The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.Type: GrantFiled: June 15, 2012Date of Patent: October 7, 2014Assignee: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo, Lauren Costantini, Sofie Kleppner
-
Publication number: 20140271765Abstract: The invention described herein solves the challenges encountered in providing a safe, efficacious, and satisfactory option for the treatment of opioid addiction. Methods and devices of the invention allow a subject to receive an implantable formulation comprising an opioid receptor ligand, buprenorphine, or a metabolite thereof as a treatment for opioid addiction. The invention preempts several difficulties encountered with conventional methods for the treatment of opioid addiction, and by doing so the invention improves treatment adherence, compliance, subject satisfaction, and overall success rate.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Titan Pharmaceuticals, Inc.Inventor: Rajesh Patel
-
Publication number: 20140271766Abstract: The invention described herein solves the challenges encountered in providing a safe, efficacious, and satisfactory option for the treatment of opioid addiction. Methods and devices of the invention allow a subject to receive an implantable formulation comprising an opioid receptor ligand, buprenorphine, or a metabolite thereof as a treatment for opioid addiction. The invention preempts several difficulties encountered with conventional methods for the treatment of opioid addiction, and by doing so the invention improves treatment adherence, compliance, patient satisfaction, and overall success rate.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Titan Pharmaceuticals, Inc.Inventor: Rajesh Patel
-
Publication number: 20140171457Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.Type: ApplicationFiled: November 26, 2013Publication date: June 19, 2014Applicant: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo
-
Publication number: 20140163057Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.Type: ApplicationFiled: November 26, 2013Publication date: June 12, 2014Applicant: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo
-
Publication number: 20140161860Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.Type: ApplicationFiled: November 26, 2013Publication date: June 12, 2014Applicant: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo
-
Publication number: 20140088131Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.Type: ApplicationFiled: November 26, 2013Publication date: March 27, 2014Applicant: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo
-
Publication number: 20130202673Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 13, 2013Publication date: August 8, 2013Applicant: Titan Pharmaceuticals, Inc.Inventor: Titan Pharmaceuticals, Inc.
-
Publication number: 20130195951Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Titan Pharmaceuticals, Inc.Inventor: Titan Pharmaceuticals, Inc.
-
Publication number: 20130195950Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Titan Pharmaceuticals, Inc.Inventor: Titan Pharmaceuticals, Inc.
-
Publication number: 20130189342Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 16, 2011Publication date: July 25, 2013Applicant: TITAN PHARMACEUTICALS, INC.Inventors: Rajesh A. Patel, Sunil R. Bhonsle
-
Publication number: 20100249235Abstract: The invention provides methods and compositions for stimulating weight loss or lowering triglyceride levels in an individual in need thereof. In methods of the invention, a pharmaceutical composition comprising a therapeutically effective amount of DITPA, and optionally one or a plurality of lipid lowering agents, is administered to an individual to stimulate weight loss, lower triglyceride and/or lipoprotein levels, and/or to treat one or more symptoms of metabolic syndrome.Type: ApplicationFiled: February 27, 2008Publication date: September 30, 2010Applicants: TITAN PHARMACEUTICALS, INC., THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Eugene Morkin, Louis R. Bucalo, Steven Goldman
-
Patent number: 7736665Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.Type: GrantFiled: June 2, 2003Date of Patent: June 15, 2010Assignee: Titan Pharmaceuticals, Inc.Inventors: Rajesh A. Patel, Louis R. Bucalo
-
Publication number: 20080026031Abstract: The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.Type: ApplicationFiled: May 8, 2007Publication date: January 31, 2008Applicant: Titan Pharmaceuticals, Inc.Inventors: Rajesh Patel, Louis Bucalo
-
Publication number: 20060292128Abstract: The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the negative symptoms of schizophrenia and/or EPS. The therapeutic cells may be coadministered with cells which protect the therapeutic cells from immune rejection and/or cells which produce neurotrophic factors which improve the viability of the therapeutic cells.Type: ApplicationFiled: August 1, 2006Publication date: December 28, 2006Applicant: Titan Pharmaceuticals, Inc.Inventors: Richard Allen, Michael Cornfeldt
-
Patent number: 7115256Abstract: The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the negative symptoms of schizophrenia and/or EPS. The therapeutic cells may be coadministered with cells which protect the therapeutic cells from immune rejection and/or cells which produce neurotrophic factors which improve the viability of the therapeutic cells.Type: GrantFiled: April 9, 1999Date of Patent: October 3, 2006Assignee: Titan Pharmaceuticals, Inc.Inventors: Richard C. Allen, Michael Cornfeldt